Local and Systemic Drug Delivery Using Responsive Microneedles
Source abstract
Abstract
Microneedles (μNDs) have emerged as promising minimally invasive drug delivery systems, offering advantages such as painless administration and enhanced drug permeability. Among various μNDs technologies, responsive μNDs have attracted growing attention for their ability to react to physiological or external stimuli, allowing precise and on-demand drug release for both localized and systemic therapies. This review explores the recent advancements in responsive μNDs triggered by various endogenous and exogenous signals that correspond to specific targeted diseases and/or sites of application. Additionally, the review highlights the challenges associated with scalability, biocompatibility, and regulatory approval of responsive μNDs and provides insights into future directions for clinical translation. By consolidating the latest developments, this review aims to support the design and optimization of next-generation smart drug delivery systems.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Hydrogels: synthesis, properties, applications · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Materials Science and Engineering
University of New South Wales (UNSW)
Curtin Medical School
Curtin University
Frazer Institute, Faculty of Medicine
University of Queensland
School of Pharmacy
Centre of Regenerative Medicine, Department of Stomatology
Renmin Hospital of Wuhan University
The Second People’s Hospital of Linhai
Australian Centre for Nanomedicine
Funding
National Health and Medical Research Council · Australian Research Council · Ramaciotti Foundations · University of New South Wales
References (100+)
Show source-provided references
1. Yadav N. · 2019 · 1
2. National Library of Medicine, National Center for Biotechnology Information, U.S. National Institutes of Health (NIH). PubMed , 2025. https://pubmed.ncbi.nlm.nih.gov/?term=topical+drug+delivery+OR+transdermal+drug+delivery&filter=years.2000-2025 (accessed 2025-07-02).
3. U.S. Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations , 2025. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book.
4. researcch, P. m. Transdermal Drug Delivery Systems Market Share, Size, Trends, Industry Analysis Report, By Type (Transdermal Patches, Transdermal Semisolids); By Technology; By Application; By Region; Segment Forecast, 2024–2032 ; 2024. https://www.polarismarketresearch.com/industry-analysis/transdermal-drug-delivery-systems-market (accessed 2025-02-07).
5. 10.1016/j.jconrel.2022.04.04310.1016/j.jconrel.2022.04.043 ↗
6. 10.1111/bph.1305910.1111/bph.13059 ↗
7. 10.1016/j.biopha.2018.10.07810.1016/j.biopha.2018.10.078 ↗
8. 10.1021/acs.biomac.1c0169110.1021/acs.biomac.1c01691 ↗
9. 10.2174/156720181666619020114345710.2174/1567201816666190201143457 ↗
10. 10.2307/153675610.2307/1536756 ↗
11. 10.1016/j.addr.2012.04.00510.1016/j.addr.2012.04.005 ↗
12. 10.1016/j.jconrel.2021.11.02510.1016/j.jconrel.2021.11.025 ↗
13. 10.3109/10717544.2014.93553210.3109/10717544.2014.935532 ↗
14. 10.1002/aic.69021052210.1002/aic.690210522 ↗
15. 10.26599/NTM.2022.913000210.26599/NTM.2022.9130002 ↗
16. 10.1159/00049747510.1159/000497475 ↗
17. 10.1016/j.biomaterials.2005.06.01910.1016/j.biomaterials.2005.06.019 ↗
18. 10.1111/jdv.1812310.1111/jdv.18123 ↗
19. 10.1007/s40820-021-00611-910.1007/s40820-021-00611-9 ↗
20. Yousef H. · 2022
21. 10.1007/978-1-4614-5034-4_1310.1007/978-1-4614-5034-4_13 ↗
22. 10.1016/j.phrs.2019.10443810.1016/j.phrs.2019.104438 ↗
23. 10.1016/j.addr.2021.11392910.1016/j.addr.2021.113929 ↗
24. 10.1016/j.heliyon.2022.e0893810.1016/j.heliyon.2022.e08938 ↗
25. 10.3390/pharmaceutics1202015210.3390/pharmaceutics12020152 ↗
26. 10.1021/mp300441c10.1021/mp300441c ↗
27. 10.1016/j.addr.2017.08.00910.1016/j.addr.2017.08.009 ↗
28. 10.1016/j.jconrel.2017.02.01110.1016/j.jconrel.2017.02.011 ↗
29. 10.1016/j.jconrel.2014.04.05210.1016/j.jconrel.2014.04.052 ↗
30. Gerstel, M.; Place, V. Drug Delivery Device. U.S. Patent No. US3964482A 1976.
31. 10.1007/s10544-005-3024-710.1007/s10544-005-3024-7 ↗
32. 10.1002/adfm.20120086410.1002/adfm.201200864 ↗
33. 10.3390/biom1306092910.3390/biom13060929 ↗
34. National Library of Medicine, National Center for Biotechnology Information, National Institutes of Health, U.S. Department of Health and Human Services. Clinical Trials , 2025. https://clinicaltrials.gov/ (accessed 2025-07-04).
35. 10.1016/j.mattod.2021.03.01210.1016/j.mattod.2021.03.012 ↗
36. 10.1016/j.biomaterials.2012.03.05610.1016/j.biomaterials.2012.03.056 ↗
37. 10.1073/pnas.150540511210.1073/pnas.1505405112 ↗
38. 10.1021/acsnano.6b0498910.1021/acsnano.6b04989 ↗
39. 10.1007/s13346-016-0328-510.1007/s13346-016-0328-5 ↗
40. 10.1002/adtp.20180003510.1002/adtp.201800035 ↗
41. 10.1021/acsami.9b0257810.1021/acsami.9b02578 ↗
42. 10.1021/acs.biomac.5b0018510.1021/acs.biomac.5b00185 ↗
43. 10.1021/acsnano.5b0397510.1021/acsnano.5b03975 ↗
44. 10.1016/j.ijpharm.2015.09.07010.1016/j.ijpharm.2015.09.070 ↗
45. 10.1098/rsfs.2017.005510.1098/rsfs.2017.0055 ↗
46. 10.1038/s41598-018-26702-z10.1038/s41598-018-26702-z ↗
47. 10.1073/pnas.071035510510.1073/pnas.0710355105 ↗
48. 10.1371/journal.pone.014564410.1371/journal.pone.0145644 ↗
49. 10.1097/DSS.000000000000297210.1097/DSS.0000000000002972 ↗
50. 10.1016/j.jconrel.2023.07.02310.1016/j.jconrel.2023.07.023 ↗
51. U. S. Food and Drug Administration. INFINI Radiofrequency System. Devices@FDA , 2013. https://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm?db=pmn&id=K121481 (accessed 2025-07-24).
52. U. S. Food and Drug Administration. 510(k) Premarket Notification , 2010. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=k092746 (accessed 2025-07-24).
53. U. S. Food and Drug Administration. SkinPen Precision Elite System. Devices@FDA , 2024. https://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm?db=pmn&id=K241400 (accessed 2025-07-24).
54. U. S. Food and Drug Administration SkinPen Precision System. Devices@FDA , 2022. https://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm?db=pmn&id=K220506 (accessed 2025-07-24).
55. U. S. Food and Drug Administration. SkinPen Precision System. Devices@FDA , 2021. https://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm?db=pmn&=K202243(accessed 2025-07-24).
56. 10.1016/j.ijpharm.2010.01.02410.1016/j.ijpharm.2010.01.024 ↗
57. 10.1007/s13346-020-00782-910.1007/s13346-020-00782-9 ↗
58. 10.1016/j.mee.2010.12.06710.1016/j.mee.2010.12.067 ↗
59. 10.1039/C6RA26759A10.1039/C6RA26759A ↗
60. 10.1016/j.msec.2016.10.06310.1016/j.msec.2016.10.063 ↗
61. 10.1016/j.jddst.2022.10311910.1016/j.jddst.2022.103119 ↗
62. 10.1016/j.bioactmat.2023.09.02210.1016/j.bioactmat.2023.09.022 ↗
63. 10.1007/s10544-023-00658-y10.1007/s10544-023-00658-y ↗
64. 10.1038/s44222-023-00141-610.1038/s44222-023-00141-6 ↗
65. 10.3762/bjnano.12.7710.3762/bjnano.12.77 ↗
66. 10.1007/978-3-662-53273-7_1910.1007/978-3-662-53273-7_19 ↗
67. 10.3389/fbioe.2023.115754110.3389/fbioe.2023.1157541 ↗
68. 10.1016/j.cej.2020.12674110.1016/j.cej.2020.126741 ↗
69. 10.1021/acsami.8b0956310.1021/acsami.8b09563 ↗
70. 10.1007/s10544-021-00576-x10.1007/s10544-021-00576-x ↗
71. 10.1016/j.jconrel.2010.10.03310.1016/j.jconrel.2010.10.033 ↗
72. 10.1021/acsnano.1c0325210.1021/acsnano.1c03252 ↗
73. 10.1039/D4TB01856G10.1039/D4TB01856G ↗
74. 10.1038/s41551-018-0337-410.1038/s41551-018-0337-4 ↗
75. 10.1016/j.jddst.2022.10363910.1016/j.jddst.2022.103639 ↗
76. 10.1097/AJP.0b013e31816778f910.1097/AJP.0b013e31816778f9 ↗
77. 10.1016/j.cherd.2008.06.00210.1016/j.cherd.2008.06.002 ↗
78. 10.1016/j.ijpharm.2010.02.00710.1016/j.ijpharm.2010.02.007 ↗
79. 10.1016/j.jconrel.2012.01.04210.1016/j.jconrel.2012.01.042 ↗
80. 10.1007/s10544-014-9861-510.1007/s10544-014-9861-5 ↗
81. 10.1016/j.ejps.2008.06.01610.1016/j.ejps.2008.06.016 ↗
82. 10.1016/j.jconrel.2010.07.10410.1016/j.jconrel.2010.07.104 ↗
83. 10.1016/j.ijpharm.2020.11967310.1016/j.ijpharm.2020.119673 ↗
84. 10.1002/adfm.20211326910.1002/adfm.202113269 ↗
85. 10.1016/j.snb.2004.04.02410.1016/j.snb.2004.04.024 ↗
86. 10.1016/j.biomaterials.2007.12.04810.1016/j.biomaterials.2007.12.048 ↗
87. 10.1080/01694243.2012.70510110.1080/01694243.2012.705101 ↗
88. 10.1186/s40486-022-00165-410.1186/s40486-022-00165-4 ↗
89. 10.1038/s41378-019-0088-810.1038/s41378-019-0088-8 ↗
90. 10.1021/acsbiomaterials.4c0090510.1021/acsbiomaterials.4c00905 ↗
91. 10.1016/j.jbiomech.2003.12.01010.1016/j.jbiomech.2003.12.010 ↗
92. 10.1016/j.addr.2018.03.01110.1016/j.addr.2018.03.011 ↗
93. 10.1016/j.jmbbm.2014.09.01510.1016/j.jmbbm.2014.09.015 ↗
94. 10.1080/1061186X.2016.120058910.1080/1061186X.2016.1200589 ↗
95. 10.1016/j.ijpharm.2014.05.04210.1016/j.ijpharm.2014.05.042 ↗
96. 10.1016/j.ijpharm.2017.02.01110.1016/j.ijpharm.2017.02.011 ↗
97. 10.3390/ma1109162510.3390/ma11091625 ↗
98. 10.1039/D3MH00352C10.1039/D3MH00352C ↗
99. 10.1016/j.mser.2016.03.00110.1016/j.mser.2016.03.001 ↗
100. 10.1016/j.jddst.2020.10192310.1016/j.jddst.2020.101923 ↗